Diabetes Management Technologies 2025-2035: Markets, Players, and Forecasts

Electrochemical glucose test strips, continuous glucose monitors (CGM), insulin pumps, insulin pens, and hybrid closed-loop artificial pancreas. Analysis and forecast of diabetes management devices market 2010-2035.

Show All Description Contents, Table & Figures List Pricing Related Content
This IDTechEx report on diabetes management technologies and markets covers the entire landscape of medical devices, including mature, emerging and future options. The report discusses key technologies and companies in electrochemical glucose test strips, continuous glucose monitoring, insulin pens, insulin pumps, automated insulin delivery. Progress in emerging technologies such as non-invasive glucose monitoring is also discussed in the report. This IDTechEx report contains historical market data and ten-year market forecasts across four key product categories to 2035.
 
The diabetes management device market has seen major changes over the past decade. At the center is the shift from electrochemical glucose test strips that require fingers to be pricked towards minimally invasive continuous glucose monitors (CGMs). The multibillion-dollar test strip industry has been in steady decline since the 2010s while the CGM companies have experienced consistent growth. IDTechEx predicts that by 2035, annual revenues from glucose test strips will only make up 5.15% of the total market for diabetes management devices.
 
Diabetes management market, diabetes technology market, continuous glucose monitoring market, insulin pump market, closed-loop insulin
Annual revenue for continuous glucose monitoring (CGM) has overtaken that of self-monitoring blood glucose (including glucose test strips).
 
Glucose sensors: Past, present, and future
People with diabetes have historically used glucose test strips to monitor their blood glucose levels. The glucose testing market was valued at over US$7.8 billion in 2010, and was based on a high margin, razor blade business model. However, a combination of pricing pressures, more stringent reimbursement policies, and the shift of users to CGMs have been driving the decline of the test strip industry. Combined, these factors have resulted in former blood glucose testing market leaders divesting their diabetes divisions, and a shift of market share to players in East Asia.
 
On the other hand, the CGM market has seen rapid growth over the past decade. IDTechEx estimates a CAGR of 30% between 2015 and 2025. The shift from discrete to continuous monitoring is expected to continue over the next ten years, including expanding reimbursement around the world to include people with type 2 diabetes. In this report we discuss the outlook for both the glucose test strip market and CGM market going forward, along with ten-year market forecasts.
 
Insulin delivery: Progress towards closing the loop
Insulin delivery is the other half of the diabetes management market. Currently, for most people with diabetes, insulin is delivered using insulin pens. Over the next ten years, IDTechEx expects more people to shift from using insulin pens towards insulin pump therapy. Key drivers of this include new insulin pumps coming to market, new form factors such as the insulin patch pump, and the advancement of insulin delivery algorithms (and integration with CGMs). The further development of insulin delivery algorithms, and automated insulin delivery (AID) systems, will be key to the insulin pump market.
Diabetes management market, diabetes technology market, continuous glucose monitoring market, insulin pump market, closed-loop insulin
The market for insulin pumps in 2023 is led by Insulet and Medtronic.
 
Digital health: Expansion of CGM into type 2 diabetes
Digital health plays a central role in diabetes management. Today, the advancement of connected medical devices such as CGMs, insulin pumps, and connected glucometers and smart insulin pens are enabling a wealth of data to be analyzed and shared online. In addition to easing some of the burden of diabetes management, digital health can provide context and education to people with diabetes. For example, a connected insulin pen, when combined with a CGM, can help users see the impact of each insulin dose on their blood glucose. Similarly, the expansion of CGMs into the consumer, prediabetes and type 2 diabetes markets will provide insight into how user's food and lifestyle choices impact their blood glucose levels.
 
Diabetes management device market analysis and forecasts
The glucose sensing and insulin delivery industries are highly interlinked - developments within one industry cause significant effects on others. IDTechEx have analyzed the entire market to produce a cohesive story, tying together developments and future milestones across the diabetes management industry to provide a realistic forecast of each individual market.
 
This report analyzes the technological and competitive landscapes of diabetes management, identifying and reviewing over 100 companies ranging from industry leaders to startups. It identifies key players in each sector along with partnerships across several industries.
Report MetricsDetails
Historic Data2010 - 2024
CAGRThe global market for diabetes management technologies will grow at CAGR 5.21% from 2025-2035
Forecast Period2025 - 2035
Forecast UnitsRevenue (US$ billions)
Regions CoveredWorldwide
Segments CoveredSelf monitoring blood glucose (including glucose readers and electrochemical glucose test strips), continuous glucose monitors (CGM), insulin pumps, tethered insulin pumps, insulin patch pumps, insulin pens.
Analyst access from IDTechEx
All report purchases include up to 30 minutes telephone time with an expert analyst who will help you link key findings in the report to the business issues you're addressing. This needs to be used within three months of purchasing the report.
Further information
If you have any questions about this report, please do not hesitate to contact our report team at research@IDTechEx.com or call one of our sales managers:

AMERICAS (USA): +1 617 577 7890
ASIA (Japan): +81 3 3216 7209
EUROPE (UK) +44 1223 812300
1.EXECUTIVE SUMMARY AND CONCLUSIONS
1.1.Executive introduction
1.2.Executive introduction
1.3.Introduction to diabetes
1.4.The cost of diabetes
1.5.Blood glucose management basics
1.6.Diabetes management device roadmap: Summary
1.7.Diabetes management device roadmap: Glucose sensors
1.8.Blood glucose monitoring test strips and associated readers
1.9.Continuous glucose monitoring
1.10.Focus shifts from glucose test strips to CGMs
1.11.When will non-invasive glucose monitoring be commercialized?
1.12.Diabetes management device roadmap: Insulin delivery
1.13.Insulin pens
1.14.Insulin pumps
1.15.Introduction to automated insulin delivery (AID) systems
1.16.Closing the loop will drive further insulin pump uptake
1.17.Digital health is at the core of diabetes management
1.18.Diabetes device industry market forecast 2025-2035
1.19.Diabetes device industry market forecast 2025-2035: Discussion
1.20.Access More With an IDTechEx Subscription
2.INTRODUCTION
2.1.1.Introduction to diabetes
2.1.2.Diabetes is on the rise
2.1.3.The cost of diabetes
2.1.4.Type 1 Diabetes vs Type 2 Diabetes
2.1.5.Blood glucose levels: Hyperglycemia and hypoglycemia
2.1.6.Medical devices for diabetes self management
2.1.7.Diabetes management device roadmap: Summary
2.1.8.Diabetes management device roadmap: Glucose sensors
2.1.9.Diabetes management device roadmap: Insulin delivery
2.2.Introduction to Key Diabetes Management Players
2.2.1.Key diabetes management companies covered in this report
2.2.2.Roche Diabetes Care
2.2.3.Abbott Diabetes Care
2.2.4.Dexcom
2.2.5.Medtronic Diabetes Operating Unit
2.2.6.Novo Nordisk Diabetes Care
2.2.7.Insulet
3.GLUCOSE SENSORS
3.1.Introduction to Glucose Sensors
3.1.1.History of glucose monitoring
3.1.2.History of glucose monitoring
3.1.3.Glucose monitoring: Key players
3.1.4.Diabetes management device roadmap: Glucose sensors
3.1.5.Key criteria for assessing accuracy
3.1.6.Glucose oxidase: Introduction
3.1.7.Glucose oxidase: Mechanism
3.1.8.Glucose dehydrogenase: Introduction
3.1.9.Glucose dehydrogenase: Mechanism and mediators
3.1.10.Glucose dehydrogenase vs glucose oxidase
3.1.11.Glucose dehydrogenase vs glucose oxidase: Advantages and disadvantages
3.1.12.The generations of glucose sensors
3.1.13.The generations of glucose sensors
3.1.14.The generations of glucose sensors: Advantages and disadvantages
3.2.Self-Monitoring Blood Glucose: Glucose Test Strips
3.2.1.Blood glucose monitoring test strips and associated readers
3.2.2.Anatomy of a glucose test strip
3.2.3.Electrode deposition: Screen printing vs sputtering
3.2.4.Companies utilize multiple manufacturing methods
3.2.5.Innovation shifts from test strip development to increasing digitalization
3.3.Self-Monitoring Blood Glucose: Market and Key Players
3.3.1.Blood glucose monitoring: Business model
3.3.2.Blood glucose monitoring: Market share
3.3.3.Roche Diabetes Care: Accu-Chek
3.3.4.Roche Diabetes Care: SMBG revenue
3.3.5.Abbott Diabetes Care: FreeStyle Optium
3.3.6.LifeScan: OneTouch
3.3.7.Challenges to the blood glucose monitoring market
3.3.8.Cost of glucose test strips vs continuous glucose monitors
3.3.9.Glucose test strips: Market outlook
3.4.Continuous Glucose Monitoring (CGM)
3.4.1.Continuous glucose monitoring
3.4.2.Benefits of continuous glucose monitoring
3.4.3.Anatomy of a typical CGM device
3.4.4.CGM technology
3.4.5.CGM sensor chemistry: Abbott, Dexcom, Medtronic
3.4.6.CGM sensor chemistry: Fluorescence-based glucose sensing
3.4.7.CGM sensor anatomy and manufacturing
3.4.8.CGM sensor filament structure
3.4.9.Implantable glucose sensors
3.4.10.Foreign body response to CGM devices
3.4.11.CGMs move to factory calibration
3.4.12.Comparison of recently launched CGM devices
3.4.13.Accuracy of CGM devices over time
3.4.14.Interference of medication with CGM accuracy
3.4.15.Predictive glucose and the potential for artificial intelligence
3.5.Continuous Glucose Monitoring: Market and Key Players
3.5.1.Focus shifts from glucose test strips to CGMs
3.5.2.CGM: overview of key players
3.5.3.Abbott Diabetes Care: FreeStyle Libre
3.5.4.Abbott Diabetes Care: Wired enzyme technology
3.5.5.Abbott Diabetes Care: Sensor structure
3.5.6.Dexcom: G6 & G7
3.5.7.Dexcom: ONE, ONE+, Stelo
3.5.8.Senseonics: Eversense
3.5.9.Senseonics: Sensor technology
3.5.10.Implantable CGMs
3.5.11.Reimbursement of CGM technologies grows
3.5.12.CGM markets in Asia
3.5.13.New entrants in the CGM market
3.5.14.Clinician concern for CGMs in type 2 diabetes
3.5.15.Reimbursement for type 2 diabetes is currently limited
3.5.16.Direct to consumer CGMs for T2D and wellness
3.5.17.CGM in hospitals
3.5.18.CGM: market outlook
3.6.Non-Invasive Glucose Monitoring Technology
3.6.1.Non-invasive glucose monitoring
3.6.2.In context: FDA requirements for blood glucose monitoring
3.6.3.FDA safety communication on non-invasive smart watches
3.6.4.Non-invasive techniques for blood and interstitial glucose
3.6.5.Summary of non-invasive glucose sensing techniques
3.6.6.Near-infrared (NIR) and short-wave infrared (SWIR) spectroscopy
3.6.7.Mid-infrared spectroscopy
3.6.8.Raman spectroscopy
3.6.9.Optical rotation
3.6.10.Dielectric spectroscopy
3.6.11.Transdermal techniques
3.6.12.Reverse iontophoresis
3.6.13.Assessment of different analytes for non-invasive glucose monitoring
3.6.14.Measuring glucose in sweat
3.6.15.Measuring glucose in tears
3.6.16.Measuring glucose in saliva
3.6.17.Measuring glucose in breath
3.6.18.Measuring glucose in urine
3.6.19.When will non-invasive glucose monitoring be commercialized?
3.6.20.Non-invasive glucose sensing techniques: Company landscape
4.INSULIN DELIVERY
4.1.Introduction to Insulin Delivery
4.1.1.Insulin
4.1.2.Delivering insulin is a critical part of diabetes management
4.1.3.Types of insulin and their use cases
4.1.4.Comparison of different types of insulin
4.1.5.Short-acting (bolus) insulin
4.1.6.Long-acting (basal) insulin
4.1.7.Diabetes management device roadmap: Insulin delivery
4.2.Insulin Pens
4.2.1.Insulin pens
4.2.2.Smarter insulin delivery informing decisions
4.2.3.Smart insulin pen: Essential functions
4.2.4.Growing digital health market drives smart pen uptake
4.2.5.Overview of commercial smart pen devices
4.2.6.Novo Nordisk: FlexPen, FlexTouch, NovoPen 6, & NovoPen Echo Plus
4.2.7.Outlook for insulin pens
4.3.Insulin Pumps
4.3.1.Insulin pumps
4.3.2.Insulin patch pumps
4.3.3.Insulin pump breakdown
4.3.4.Overview of commercial insulin pumps
4.3.5.Barriers to insulin pump adoption
4.3.6.Device security: Implications for insulin pumps
4.4.Insulin Pumps: Market and Key Players
4.4.1.Insulin pump market
4.4.2.Insulin pump market: Overview of key players
4.4.3.Technology innovations drive insulin pump market
4.4.4.The rise of the tubeless insulin pumps
4.4.5.Pricing models for patch pumps vs tethered pumps
4.4.6.Medtronic: MiniMed 780G
4.4.7.Insulet: Omnipod 5
4.4.8.Insulet: Omnipod DASH, Omnipod GO
4.4.9.Insulin pumps: Market outlook
4.5.Alternative Insulin Technologies
4.5.1.Non-invasive insulin delivery methods
4.5.2.Assessment of different routes for non-invasive insulin delivery
4.5.3.Inhaled insulin: Introduction
4.5.4.Inhaled insulin: Commercial challenges
4.5.5.Oral insulin
4.5.6.Buccal insulin
4.5.7.Transdermal insulin
4.5.8.Non-invasive insulin: Barriers to market adoption
4.5.9.Glucose-responsive insulin
4.5.10.The poor track record in non-invasive insulin
5.TOWARDS CLOSED-LOOP SYSTEMS AND ARTIFICIAL PANCREAS
5.1.Introduction to automated insulin delivery (AID) systems
5.2.Insulin pump technology roadmap
5.3.Interoperability essential to new hybrid closed-loop systems
5.4.Advanced hybrid closed-loop
5.5.Model predictive control
5.6.PID control
5.7.Case study: Progress from Medtronic
5.8.Medtronic: SmartGuard and Meal Detection
5.9.Medtronic: SmartGuard and Meal Detection
5.10.Dexcom: Partnerships for hybrid-closed loop systems
5.11.Interoperable automated glycemic controllers (iAGCs)
5.12.Progress towards automated insulin delivery
6.DIGITAL HEALTH
6.1.Diabetes is an early adopter of digital healthcare initiatives
6.2.Diabetes digital health landscape
6.3.Diabetes management apps: Ecosystem
6.4.Diabetes management apps
6.5.Digital health and connected diabetes management hardware
6.6.CGM integration with mobile apps
6.7.Lifestyle management apps: Focal points
6.8.Diet management: Meal tracking and diet planning
6.9.Telehealth in diabetes: Introduction
6.10.Regulatory requirements: Telemedicine
6.11.Telehealth in Type 2 and pre-diabetes: Examples
6.12.Addressing prediabetes via digital health
6.13.Digital health programs: Evidence for type 2 diabetes
6.14.Digital health and diabetes: Outlook
7.ADVANCED THERAPIES FOR DIABETES
7.1.Diabetes management device roadmap: Advanced therapies
7.2.Advanced therapies: Introduction
7.3.Cell therapy devices for type 1 diabetes
7.4.Advanced therapies: Conclusions
8.TECHNOLOGIES FOR DIABETES COMPLICATIONS
8.1.Introduction
8.1.1.Managing side effects accounts for 90% of the total cost of diabetes
8.2.Diabetic Ketoacidosis
8.2.1.Diabetic ketoacidosis: Introduction
8.2.2.Ketone monitoring: Electrochemical sensors
8.2.3.Ketone monitoring: Urine test strips
8.2.4.Ketone monitoring: Outlook
8.2.5.Diabetic Neuropathy & Retinopathy
8.2.6.Diabetic neuropathy and diabetic foot ulcers
8.2.7.Diabetic foot ulcers: Smart footwear for monitoring
8.2.8.Diabetic retinopathy: Introduction
8.2.9.Diabetic retinopathy: AI image recognition software
8.2.10.Diabetic retinopathy: Wearable vision aids
8.2.11.Diabetic neuropathy and retinopathy: Outlook
9.MARKET FORECASTS
9.1.Introduction
9.2.Market sizing and forecast methodology
9.3.Diabetes device industry market forecast 2025-2035
9.4.Diabetes device industry market forecast by proportion 2025-2035
9.5.Diabetes device industry market forecast 2025-2035: Discussion
9.6.Self monitoring blood glucose market forecast 2025-2035
9.7.Self monitoring blood glucose market forecast 2025-2035: Discussion
9.8.CGM market forecast 2025-2035
9.9.CGM market forecast 2025-2035: Discussion
9.10.Insulin pen market forecast 2025-2035
9.11.Insulin pump market forecast 2025-2035
9.12.Insulin pump market forecast 2025-2035: Discussion
9.13.Tethered insulin pump market forecast 2025-2035
9.14.Insulin patch pump market forecast 2025-2035
10.COMPANY PROFILES
10.1.Abbott Diabetes Care
10.2.Abbott Diabetes Care update
10.3.AgaMatrix
10.4.Alpha Pharma
10.5.Artelus
10.6.Beta Bionics
10.7.Bionime
10.8.CamDiab
10.9.Carbometrics
10.10.CNOGA Medical
10.11.Dexcom
10.12.Dexcom update
10.13.DiabeLoop
10.14.Diabeloop update
10.15.DiaMonTech
10.16.Digital Diagnostics (formerly known as IDx)
10.17.Fitscript
10.18.Glooko
10.19.Glooko update
10.20.GlucoRx
10.21.GlucoRx (BioXensor)
10.22.i-Sens
10.23.Impeto Medical
10.24.Infinovo
10.25.Inreda Diabetic
10.26.Insulet
10.27.Kriya Therapeutics
10.28.MannKind
10.29.Medtronic (Diabetes Division)
10.30.Medtronic Diabetes
10.31.Medtrum Technologies
10.32.National Diagnostic Products
10.33.Nemaura Medical
10.34.Orpyx
10.35.PKvitality
10.36.PKVitality update
10.37.Quantum Operation
10.38.RSP Systems
10.39.RSP Systems update
10.40.Senseonics
10.41.Siren Care Denmark
10.42.SNAQ
10.43.SOOIL Development
10.44.TaiDoc
10.45.Tidepool
10.46.Welldoc: Diabetes
 

Ordering Information

Diabetes Management Technologies 2025-2035: Markets, Players, and Forecasts

£$¥
Electronic (1-5 users)
£5,650.00
Electronic (6-10 users)
£8,050.00
Electronic and 1 Hardcopy (1-5 users)
£6,450.00
Electronic and 1 Hardcopy (6-10 users)
£8,850.00
Electronic (1-5 users)
€6,400.00
Electronic (6-10 users)
€9,100.00
Electronic and 1 Hardcopy (1-5 users)
€7,310.00
Electronic and 1 Hardcopy (6-10 users)
€10,010.00
Electronic (1-5 users)
$7,000.00
Electronic (6-10 users)
$10,000.00
Electronic and 1 Hardcopy (1-5 users)
$7,975.00
Electronic and 1 Hardcopy (6-10 users)
$10,975.00
Electronic (1-5 users)
元50,000.00
Electronic (6-10 users)
元72,000.00
Electronic and 1 Hardcopy (1-5 users)
元58,000.00
Electronic and 1 Hardcopy (6-10 users)
元80,000.00
Electronic (1-5 users)
¥990,000
Electronic (6-10 users)
¥1,406,000
Electronic and 1 Hardcopy (1-5 users)
¥1,140,000
Electronic and 1 Hardcopy (6-10 users)
¥1,556,000
Click here to enquire about additional licenses.
If you are a reseller/distributor please contact us before ordering.
お問合せ、見積および請求書が必要な方はm.murakoshi@idtechex.com までご連絡ください。
The market for diabetes management technologies will reach US$44 billion in 2035.

Report Statistics

Slides 246
Forecasts to 2035
Published Dec 2024
 

Preview Content

pdf Document Sample pages
 
 
 
 
ISBN: 9781835700860

Subscription Enquiry